Skip to Main Content
Clinical Diagnostics

GeneCount® COVID-19 RT-qPCR Testing Solutions

Comprehensive solutions for ongoing pathogen defense

  • Equipment sets and test kits include all materials required to carry out testing – just unpack and get started*
  • GeneCount® platforms can also test environments including surfaces, air and wastewater for the presence of SARS-CoV-2, providing a holistic approach to pandemic management
  • Ask us about our complete range of qPCR assays for other bacteria and viruses in a variety of sample types

*User must supply ethanol.

COVID-19 virus

Convenient and easy-to-use platforms deliver fast results

  • Gold-standard RT-qPCR methods let you test with confidence:
    • Fully portable manual testing using
      GeneCount® Q-16
    • Automated high-throughput testing with GeneCount® Q-96
  • Results available in under 2 hours from sample collection to result interpretation
  • Software and testing materials are built to ensure accuracy while maximizing ease of use in execution and interpretation of data

GeneCount qPCR - Q-16 & Q-96

Reliable supply and industry-leading service

  • LuminUltra is a key supplier to the Government of Canada, providing RNA Isolation Kits for 500,000 tests/week to meet national need
    Public Health Agency of Canada logo
  • State-of-the-art facilities, production and supply chain expertise ensure the ability to meet high-volume needs
  • Long history of supporting a variety of markets with personalized service that ensures quality results
GeneCount RNA isolation kit

Complete testing workflows to fit your needs

Instructions for use

View instructions

LuminUltra’s COVID-19 clinical testing solutions

LuminUltra’s complete COVID-19 testing solutions give governments and businesses the tools they need to deliver a high volume of the most accurate COVID-19 test results possible in under two hours. Learn how these products can be tailored to your specific needs.

Compliance Statements
  • The LuminUltra GeneCount® COVID-19 RT-qPCR Assay Kit has completed the Section IV.C notification process under FDA’s “Policy for Coronavirus Disease-2019 Tests During the Public Health Emergency (Revised)” and has not been reviewed by FDA
  • Health Canada has granted an Interim Order authorizing all devices included in the submission, to be imported, sold and advertised in Canada, for the duration that the Interim Order is in effect.
  • Additional application pending with the European Union for CE IVD.
  • All tests must be conducted in accordance with the local laws and regulations.
Your browser is out of date!

Update your browser to view this website correctly. Update my browser now